The global market for Viral Vector Manufacturing CDMO Services was valued at US$ 5231 million in the year 2023 and is projected to reach a revised size of US$ 9450 million by 2030, growing at a CAGR of 9.2% during the forecast period.
Viral Vector Manufacturing CDMO services refer to providing professional viral vector production and development services to biopharmaceutical companies. These viral vectors are usually used in gene therapy, vaccine development, cell therapy and other fields. CDMO organizations are responsible for the design and optimization of viral vectors to large-scale production in accordance with GMP standards, ensuring the safety and effectiveness of the products, while strictly controlling the quality of each production link. These services provide key technical support for biopharmaceutical companies to help accelerate the development and commercialization of their products.
North American market for Viral Vector Manufacturing CDMO Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Viral Vector Manufacturing CDMO Services is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Viral Vector Manufacturing CDMO Services in Gene Therapy is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Viral Vector Manufacturing CDMO Services include Thermo Fisher Scientific Inc., Revvity, Charles River Laboratories, AGC Inc. Group (AGC Biologics), NorthX Biologics, Lonza, Avid Bioservices, Inc., Exothera, Merck KGaA, Batavia Biosciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Viral Vector Manufacturing CDMO Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector Manufacturing CDMO Services.
The Viral Vector Manufacturing CDMO Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vector Manufacturing CDMO Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector Manufacturing CDMO Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Thermo Fisher Scientific Inc.
Revvity
Charles River Laboratories
AGC Inc. Group (AGC Biologics)
NorthX Biologics
Lonza
Avid Bioservices, Inc.
Exothera
Merck KGaA
Batavia Biosciences
SK pharmteco Inc.
Biovian
Curia Vector Technology
Esco Aster
ABL, Inc.
Genezen
Pharmaron
Roche AG
FinVector
FUJIFILM Diosynth Biotechnologies
Kaneka Eurogentec S.A. (Kaneka Corporation)
Oxford Biomedica plc
Sanofi S.A.
Segment by Type
Adeno-associated Virus
Lentivirus
Retrovirus
Adenovirus
Other
Segment by Application
Gene Therapy
Vaccine Development
Cell Therapy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vector Manufacturing CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Viral Vector Manufacturing CDMO Services 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Adeno-associated Virus
1.2.3 Lentivirus
1.2.4 Retrovirus
1.2.5 Adenovirus
1.2.6 Other
1.3 麻豆原创 by Application
1.3.1 Global Viral Vector Manufacturing CDMO Services 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Gene Therapy
1.3.3 Vaccine Development
1.3.4 Cell Therapy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vector Manufacturing CDMO Services 麻豆原创 Perspective (2019-2030)
2.2 Global Viral Vector Manufacturing CDMO Services Growth Trends by Region
2.2.1 Global Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Viral Vector Manufacturing CDMO Services Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Viral Vector Manufacturing CDMO Services Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Viral Vector Manufacturing CDMO Services 麻豆原创 Dynamics
2.3.1 Viral Vector Manufacturing CDMO Services Industry Trends
2.3.2 Viral Vector Manufacturing CDMO Services 麻豆原创 Drivers
2.3.3 Viral Vector Manufacturing CDMO Services 麻豆原创 Challenges
2.3.4 Viral Vector Manufacturing CDMO Services 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral Vector Manufacturing CDMO Services Players by Revenue
3.1.1 Global Top Viral Vector Manufacturing CDMO Services Players by Revenue (2019-2024)
3.1.2 Global Viral Vector Manufacturing CDMO Services Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Viral Vector Manufacturing CDMO Services 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Viral Vector Manufacturing CDMO Services Revenue
3.4 Global Viral Vector Manufacturing CDMO Services 麻豆原创 Concentration Ratio
3.4.1 Global Viral Vector Manufacturing CDMO Services 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vector Manufacturing CDMO Services Revenue in 2023
3.5 Global Key Players of Viral Vector Manufacturing CDMO Services Head office and Area Served
3.6 Global Key Players of Viral Vector Manufacturing CDMO Services, Product and Application
3.7 Global Key Players of Viral Vector Manufacturing CDMO Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vector Manufacturing CDMO Services Breakdown Data by Type
4.1 Global Viral Vector Manufacturing CDMO Services Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Viral Vector Manufacturing CDMO Services Forecasted 麻豆原创 Size by Type (2025-2030)
5 Viral Vector Manufacturing CDMO Services Breakdown Data by Application
5.1 Global Viral Vector Manufacturing CDMO Services Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Viral Vector Manufacturing CDMO Services Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Viral Vector Manufacturing CDMO Services 麻豆原创 Size (2019-2030)
6.2 North America Viral Vector Manufacturing CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Country (2019-2024)
6.4 North America Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Viral Vector Manufacturing CDMO Services 麻豆原创 Size (2019-2030)
7.2 Europe Viral Vector Manufacturing CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Country (2019-2024)
7.4 Europe Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Viral Vector Manufacturing CDMO Services 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Viral Vector Manufacturing CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Viral Vector Manufacturing CDMO Services 麻豆原创 Size (2019-2030)
9.2 Latin America Viral Vector Manufacturing CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral Vector Manufacturing CDMO Services 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Viral Vector Manufacturing CDMO Services 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Viral Vector Manufacturing CDMO Services 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific Inc.
11.1.1 Thermo Fisher Scientific Inc. Company Details
11.1.2 Thermo Fisher Scientific Inc. Business Overview
11.1.3 Thermo Fisher Scientific Inc. Viral Vector Manufacturing CDMO Services Introduction
11.1.4 Thermo Fisher Scientific Inc. Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.1.5 Thermo Fisher Scientific Inc. Recent Development
11.2 Revvity
11.2.1 Revvity Company Details
11.2.2 Revvity Business Overview
11.2.3 Revvity Viral Vector Manufacturing CDMO Services Introduction
11.2.4 Revvity Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.2.5 Revvity Recent Development
11.3 Charles River Laboratories
11.3.1 Charles River Laboratories Company Details
11.3.2 Charles River Laboratories Business Overview
11.3.3 Charles River Laboratories Viral Vector Manufacturing CDMO Services Introduction
11.3.4 Charles River Laboratories Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.3.5 Charles River Laboratories Recent Development
11.4 AGC Inc. Group (AGC Biologics)
11.4.1 AGC Inc. Group (AGC Biologics) Company Details
11.4.2 AGC Inc. Group (AGC Biologics) Business Overview
11.4.3 AGC Inc. Group (AGC Biologics) Viral Vector Manufacturing CDMO Services Introduction
11.4.4 AGC Inc. Group (AGC Biologics) Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.4.5 AGC Inc. Group (AGC Biologics) Recent Development
11.5 NorthX Biologics
11.5.1 NorthX Biologics Company Details
11.5.2 NorthX Biologics Business Overview
11.5.3 NorthX Biologics Viral Vector Manufacturing CDMO Services Introduction
11.5.4 NorthX Biologics Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.5.5 NorthX Biologics Recent Development
11.6 Lonza
11.6.1 Lonza Company Details
11.6.2 Lonza Business Overview
11.6.3 Lonza Viral Vector Manufacturing CDMO Services Introduction
11.6.4 Lonza Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.6.5 Lonza Recent Development
11.7 Avid Bioservices, Inc.
11.7.1 Avid Bioservices, Inc. Company Details
11.7.2 Avid Bioservices, Inc. Business Overview
11.7.3 Avid Bioservices, Inc. Viral Vector Manufacturing CDMO Services Introduction
11.7.4 Avid Bioservices, Inc. Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.7.5 Avid Bioservices, Inc. Recent Development
11.8 Exothera
11.8.1 Exothera Company Details
11.8.2 Exothera Business Overview
11.8.3 Exothera Viral Vector Manufacturing CDMO Services Introduction
11.8.4 Exothera Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.8.5 Exothera Recent Development
11.9 Merck KGaA
11.9.1 Merck KGaA Company Details
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Viral Vector Manufacturing CDMO Services Introduction
11.9.4 Merck KGaA Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.9.5 Merck KGaA Recent Development
11.10 Batavia Biosciences
11.10.1 Batavia Biosciences Company Details
11.10.2 Batavia Biosciences Business Overview
11.10.3 Batavia Biosciences Viral Vector Manufacturing CDMO Services Introduction
11.10.4 Batavia Biosciences Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.10.5 Batavia Biosciences Recent Development
11.11 SK pharmteco Inc.
11.11.1 SK pharmteco Inc. Company Details
11.11.2 SK pharmteco Inc. Business Overview
11.11.3 SK pharmteco Inc. Viral Vector Manufacturing CDMO Services Introduction
11.11.4 SK pharmteco Inc. Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.11.5 SK pharmteco Inc. Recent Development
11.12 Biovian
11.12.1 Biovian Company Details
11.12.2 Biovian Business Overview
11.12.3 Biovian Viral Vector Manufacturing CDMO Services Introduction
11.12.4 Biovian Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.12.5 Biovian Recent Development
11.13 Curia Vector Technology
11.13.1 Curia Vector Technology Company Details
11.13.2 Curia Vector Technology Business Overview
11.13.3 Curia Vector Technology Viral Vector Manufacturing CDMO Services Introduction
11.13.4 Curia Vector Technology Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.13.5 Curia Vector Technology Recent Development
11.14 Esco Aster
11.14.1 Esco Aster Company Details
11.14.2 Esco Aster Business Overview
11.14.3 Esco Aster Viral Vector Manufacturing CDMO Services Introduction
11.14.4 Esco Aster Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.14.5 Esco Aster Recent Development
11.15 ABL, Inc.
11.15.1 ABL, Inc. Company Details
11.15.2 ABL, Inc. Business Overview
11.15.3 ABL, Inc. Viral Vector Manufacturing CDMO Services Introduction
11.15.4 ABL, Inc. Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.15.5 ABL, Inc. Recent Development
11.16 Genezen
11.16.1 Genezen Company Details
11.16.2 Genezen Business Overview
11.16.3 Genezen Viral Vector Manufacturing CDMO Services Introduction
11.16.4 Genezen Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.16.5 Genezen Recent Development
11.17 Pharmaron
11.17.1 Pharmaron Company Details
11.17.2 Pharmaron Business Overview
11.17.3 Pharmaron Viral Vector Manufacturing CDMO Services Introduction
11.17.4 Pharmaron Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.17.5 Pharmaron Recent Development
11.18 Roche AG
11.18.1 Roche AG Company Details
11.18.2 Roche AG Business Overview
11.18.3 Roche AG Viral Vector Manufacturing CDMO Services Introduction
11.18.4 Roche AG Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.18.5 Roche AG Recent Development
11.19 FinVector
11.19.1 FinVector Company Details
11.19.2 FinVector Business Overview
11.19.3 FinVector Viral Vector Manufacturing CDMO Services Introduction
11.19.4 FinVector Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.19.5 FinVector Recent Development
11.20 FUJIFILM Diosynth Biotechnologies
11.20.1 FUJIFILM Diosynth Biotechnologies Company Details
11.20.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.20.3 FUJIFILM Diosynth Biotechnologies Viral Vector Manufacturing CDMO Services Introduction
11.20.4 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.20.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.21 Kaneka Eurogentec S.A. (Kaneka Corporation)
11.21.1 Kaneka Eurogentec S.A. (Kaneka Corporation) Company Details
11.21.2 Kaneka Eurogentec S.A. (Kaneka Corporation) Business Overview
11.21.3 Kaneka Eurogentec S.A. (Kaneka Corporation) Viral Vector Manufacturing CDMO Services Introduction
11.21.4 Kaneka Eurogentec S.A. (Kaneka Corporation) Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.21.5 Kaneka Eurogentec S.A. (Kaneka Corporation) Recent Development
11.22 Oxford Biomedica plc
11.22.1 Oxford Biomedica plc Company Details
11.22.2 Oxford Biomedica plc Business Overview
11.22.3 Oxford Biomedica plc Viral Vector Manufacturing CDMO Services Introduction
11.22.4 Oxford Biomedica plc Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.22.5 Oxford Biomedica plc Recent Development
11.23 Sanofi S.A.
11.23.1 Sanofi S.A. Company Details
11.23.2 Sanofi S.A. Business Overview
11.23.3 Sanofi S.A. Viral Vector Manufacturing CDMO Services Introduction
11.23.4 Sanofi S.A. Revenue in Viral Vector Manufacturing CDMO Services Business (2019-2024)
11.23.5 Sanofi S.A. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Thermo Fisher Scientific Inc.
Revvity
Charles River Laboratories
AGC Inc. Group (AGC Biologics)
NorthX Biologics
Lonza
Avid Bioservices, Inc.
Exothera
Merck KGaA
Batavia Biosciences
SK pharmteco Inc.
Biovian
Curia Vector Technology
Esco Aster
ABL, Inc.
Genezen
Pharmaron
Roche AG
FinVector
FUJIFILM Diosynth Biotechnologies
Kaneka Eurogentec S.A. (Kaneka Corporation)
Oxford Biomedica plc
Sanofi S.A.
听
听
*If Applicable.
